Pelthos Therapeutics Inc（PTHS）價格

Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi (ozenoxacin) Cream, 1%, which is a non-fluorinated quinolone antimicrobial indicated for the topical treatment of impetigo. The firm is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.